Current Opinion in Oncology

Article	Citations
Epidemiology of head and neck cancers: an update	159
Lung cancer in China: current and prospect	140
Molecular alterations in meningioma: prognostic and therapeutic perspectives	51
Advances in immunotherapy for cervical cancer	47
Models of supportive care in oncology	35
Viral strategies for circumventing p53: the case of severe acute respiratory syndrome coronavirus	32
BRAF mutations in thyroid cancer	28
Malignant pleural mesothelioma: recent developments	26
Antibody–drug conjugates in breast cancer: the chemotherapy of the future?	24
Recent progress in treating advanced prostate cancer	24
CD19-directed CAR T-cell therapy in B-cell NHL	23
Current concepts in the treatment of giant cell tumour of bone	22
Targeting HER2 heterogeneity in early-stage breast cancer	20
Current emerging MRI tools for radionecrosis and pseudoprogression diagnosis	18
Adjuvant chemotherapy in pancreatic cancer: state of the art and future perspectives	17
Multimodality treatment for localized gastric cancer: state of the art and new insights	17
Sinonasal cancers treatments: state of the art	17
Filling the gaps of patient information and comprehension	17
Geriatric assessments and frailty scores in multiple myeloma patients: a needed tool for individualized treatment?	16
Resistance mechanisms to osimertinib and emerging therapeutic strategies in nonsmall cell lung cancer	16
The roaring 2020s: a new decade of systemic therapy for renal cell carcinoma	16
T-cell-engaging antibodies for the treatment of solid tumors: challenges and opportunities	16
Targeting SUMOylation in cancer	16
MEK inhibitors in RASopathies	15
Mechanisms of invasion in glioblastoma	14

Updated concepts in treatment of giant cell tumor of bone	14
Cabozantinib as an emerging treatment for sarcoma	14
New drugs in gastrointestinal stromal tumors	14
The role of the tumor matrix environment in progression of head and neck cancer	14
Clinical data, limitations and perspectives on chimeric antigen receptor T-cell therapy in multiple myeloma	14
Targeted radionuclide therapy: an emerging field in solid tumours	14
The emerging data on choice of optimal therapy for locally advanced nasopharyngeal carcinoma	13
Adrenocortical carcinoma: current treatment options	13
New targets and technologies for CAR-T cells	13
Adjuvant therapy of operable nonsmall cell lung cancer: an update	13
Challenges and opportunities in the management of metastatic renal cell carcinoma: combination therapy and the role of cytoreductive surgery	13
Triplet combination of BRAF, MEK and PD-1/PD-L1 blockade in melanoma: the more the better?	13
Next-generation sequencing for the management of sarcomas with no known driver mutations	13
The role of myeloid-derived suppressor cells in hematologic malignancies	13
Retroperitoneal sarcoma: the Transatlantic Australasian Retroperitoneal Sarcoma Working Group Program	13
Immunotherapy and breast cancer: an overview	13
The evolving treatment paradigm of advanced hepatocellular carcinoma: putting all the pieces back together	12
Adjuvant chemotherapy in rectal cancer: state of the art and future perspectives	12
Progress in the management of endometrial cancer (subtypes, immunotherapy, alterations in PIK3CA pathway): data and perspectives	12
Opportunities and challenges associated with the evaluation of chimeric antigen receptor T cells in real-life	12
Therapeutic targeting of the DNA damage response in prostate cancer	11
EGFR-mutant NSCLC: emerging novel drugs	11
Lifestyle and quality of life in patients with early-stage breast cancer receiving adjuvant endocrine therapy	11
Interventions addressing fear of cancer recurrence: challenges and future perspectives	10
Integrating new oral selective oestrogen receptor degraders in the breast cancer treatment	10
Management of epilepsy in brain tumor patients	10
Harnessing dendritic cells for innovative therapeutic cancer vaccines	10
Role of Poly (ADP-Ribose) Polymerase inhibitors beyond BReast CAncer Gene-mutated ovarian tumours: definition of homologous recombination deficiency?	10
Preoperative immunotherapy for head and neck cancers: state of art	10
An update on adult forms of hereditary pheochromocytomas and paragangliomas	9
Image-guided surgery in oral cancer: toward improved margin control	9
Systemic treatment of metastatic squamous cell carcinoma of the head and neck: proposal for management changes	9
Novel therapeutic options for alveolar soft part sarcoma: antiangiogenic therapy, immunotherapy and beyond	9
Overcoming key challenges in cancer immunotherapy with engineered T cells	9
Adjuvant chemotherapy in colon cancer: state of the art and future perspectives	9
Tropomyosin receptor kinase inhibitors in the management of sarcomas	9
131I-metaiodobenzylguanidine and peptide receptor radionuclide therapy in pheochromocytoma and paraganglioma	9
Indications of next-generation sequencing in non-Hodgkin's lymphoma	9
Bromodomain and extraterminal domain protein bromodomain inhibitor based cancer therapeutics	9
New perspectives on targeting RAF, MEK and ERK in melanoma	9
Treatment updates on tenosynovial giant cell tumor	9
Perspectives in pathomics in head and neck cancer	8
Recent advances in primary resistance mechanisms against immune checkpoint inhibitors	8
Immunomodulation for hepatocellular carcinoma therapy: current challenges	8
Mitogen-activating protein kinase pathway alterations in Langerhans cell histiocytosis	8
Immune escape mechanisms in head and neck squamous cell carcinoma and implication for new immunotherapy approach	8
Anaplastic thyroid carcinoma: advances in molecular profiling and targeted therapy	8
Is less more in the surgical treatment of early-stage cervical cancer?	8
Novel immunotherapeutic drugs for the treatment of lung cancer	8
Primary vitreoretinal lymphoma: short review of the literature, results of a European survey and French guidelines of the LOC network for diagnosis, treatment and follow-up	8

Combining immunotherapy and radiotherapy in head and neck squamous cell cancers: which perspectives?	8
New molecular entities of soft tissue and bone tumors	8
Lung cancer screening: a critical appraisal	7
Medical treatment of advanced malignant perivascular epithelioid cell tumors	7
Adjuvant chemotherapy in biliary tract cancer: state of the art and future perspectives	7
Beyond ibrutinib: novel BTK inhibitors for the treatment of chronic lymphocytic leukemia	7
Desmoid tumors: who, when and how to treat?	7
Current status of phosphoinotiside-3 kinase inhibitors in blood cancers	7
Prognostic factors in primary central nervous system lymphoma	7
COVID-19 and supportive cancer care: key issues and opportunities	7
Targeting microRNA in hematologic malignancies	7
Role of metabolic imaging in diagnosis of primary, metastatic, and recurrent prostate cancer	7
Epigenetic focus on angioimmunoblastic T-cell lymphoma: pathogenesis and treatment	7
Antibodies targeting Prostate-Specific Membrane Antigen positive prostate cancer: from diagnostic imaging to theranostics	6
Targeting the methionine−methionine adenosyl transferase 2A−S-adenosyl methionine axis for cancer therapy	6
Current treatments of medulloblastoma	6
Bacterial infection-driven lymphomagenesis	6
Tyrosine kinase inhibitors as induction therapy in nonsmall-cell lung cancer	6
Desmoid-type fibromatosis: toward a holistic management	6
Supportive care for new cancer therapies	6
Biomarkers and immunotherapy: where are we?	6
Cost-effectiveness of newer regimens for the prophylaxis of chemotherapy-induced nausea and vomiting: review of the literature and real-world data	6
Targeting the DNA damage response beyond poly(ADP-ribose) polymerase inhibitors: novel agents and rational combinations	6
HIPEC in advanced epithelial ovarian cancer: why is there controversy?	6
The road to chemotherapy-free treatment in chronic lymphocytic leukaemia	6
New imaging modalities to distinguish rare uterine mesenchymal cancers from benign uterine lesions	5
EBV-associated NK and T-cell lymphoid neoplasms	5
Can we cure oligometastatic disease? A practical point of view	5
Mutational burden and immune recognition of gliomas	5
Ten steps to establish a national centre for gestational trophoblastic disease	5
WHO 2021 and beyond: new types, molecular markers and tools for brain tumor classification	5
Adjuvant treatment of early male breast cancer	5
Emergency management of immune-related toxicity	5
How to treat lobular cancer in the adjuvant setting?	5
Emerging systemic antitarget treatment for differentiated thyroid carcinoma	5
Embryonal tumors of the central nervous system	5
Advances in myelodysplastic syndrome	5
A challenging frontier – the genomics and therapeutics of nonclear cell renal cell carcinoma	5
Immunotherapy combinations in advanced nonsmall cell lung cancer	5
The multiple molecular dimensions of long noncoding RNAs that regulate gene expression and tumorigenesis	5
Getting personal in metastatic melanoma: neoantigen-based vaccines as a new therapeutic strategy	5
Statistical aspects in adjuvant and neoadjuvant trials for gastrointestinal cancer in 2020: focus on time-to-event endpoints	5
The role of autologous stem-cell transplantation in multiple myeloma in 2021	5
Immunotherapy of sarcomas with modified T cells	5
Use of staging for sex cord stromal tumours	5
Integrating immunotherapy in the (neo)adjuvant setting of early breast cancer	5
Transcriptional and epigenetic control of early life cell fate decisions	5
Epigenetic in medullary thyroid cancer: the role of microRNA in tumorigenesis and prognosis	5
Multikinase inhibitors for the treatment of radioiodine refractory thyroid cancer: what have we learned from the ‘real-world’ experience?	5
Immunotherapy in multiple myeloma: when, where, and for who?	5
Neoadjuvant immunotherapy in nonsmall cell lung cancer	4
The changing landscape for patients with relapsed/refractory acute myeloid leukaemia	4
Fundamentals of liquid biopsies in metastatic prostate cancer: from characterization to stratification	4
New perspectives in liquid biopsy for glioma patients	4
Hairy cell leukemia: a brief update on current knowledge and treatment prospects	4
The evolving treatment landscape of advanced urothelial carcinoma	4
Immunotherapy in sarcoma: combinations or single agents? In whom?	4
Targeting cancer stem cell pathways for lung cancer therapy	4
Neurological complications of chimeric antigen receptor T cells and immune-checkpoint inhibitors: ongoing challenges in daily practice	4
Mitogen-activated protein kinase blockade in melanoma: intermittent versus continuous therapy, from preclinical to clinical data	4
Targeting defective DNA repair in prostate cancer	4
Understanding the tumor-immune microenvironment in prostate cancer	4
Prevention of brain metastases in human epidermal growth factor receptor 2-positive breast cancer	4
Melanoma with genetic alterations beyond the BRAF V600 mutation: management and new insights	4
The role of next-generation sequencing in acute myeloid leukemia	4
CIC-DUX4 sarcomas	4
Tropomyosin receptor kinases in sarcomas – of joy and despair	4
Circulating tumour DNA dynamics for assessment of molecular residual disease and for intercepting resistance in breast cancer	4
Angiogenesis inhibition in lung cancer: emerging novel strategies	4
Emerging role of multiparametric magnetic resonance imaging in identifying clinically relevant localized prostate cancer	4
Artificial intelligence: opportunities in lung cancer	4
Immunotherapy in gynecological cancers: where are we?	4
Epstein-Barr virus-associated posttransplant lymphoproliferative disorders: new insights in pathogenesis, classification and treatment	4
New developments in rare vulvar and vaginal cancers	4
Novel strategies to improve efficacy of treatment with tumor-infiltrating lymphocytes (TILs) for patients with solid cancers	4
Next questions for the medical treatment of gastrointestinal stromal tumor	4
Importance of guidelines and networking for the management of rare gynecological cancers	4
Challenges adopting next-generation sequencing in community oncology practice	4
Content features and its implementation in novel app-based psycho-oncological interventions for cancer survivors: a narrative review	4
New treatments in advanced gastrointestinal stromal tumor	4

Renal oncocytoma: a challenging diagnosis	3
How to support parenting in patients with cancer and co-parents? From research to practice	3
A precision medicine approach to management of acute myeloid leukemia in older adults	3
Thoracic irradiation as consolidation therapy in patients with extensive-stage small cell lung cancer	3
Editorial: Lung cancer: continuous progress in diagnosis and treatment	3
Systemic treatment of recurrent and/or metastatic squamous cell carcinomas of the head and neck: what is the best therapeutic sequence?	3
Immunotherapy in rare ovarian cancer	3
MAPK blockade, toxicities, pathogenesis and management	3
Clinical management of brain tumors in pregnancy	3
Surgical management of skull base meningiomas and vestibular schwannomas	3
Venetoclax in combination with nucleoside analogs in acute myelogenous leukemia	3
Postneoadjuvant treatment for triple-negative breast cancer	3
Psycho-oncology interventions focusing on fatigue and sleep disturbances	3
Novel treatment approaches for HER2 positive solid tumors (excluding breast cancer)	3
T-cell redirecting bispecific and trispecific antibodies in multiple myeloma beyond BCMA	3
Oral microbiome as a new research-target for supportive care and precision oncology	3
Editorial: Supportive care: do we need a model?	3
Molecular genotyping of adrenocortical carcinoma: a systematic analysis of published literature 2019–2021	3
State of the art and future directions in the systemic treatment of neuroendocrine neoplasms	3
New horizons in early drugs development in solid cancers	3
Chimeric antigen receptor T-cell lymphoma immunotherapy: the next questions	3
State of the art and future directions in the systemic treatment of medullary thyroid cancer	3
Management of metastatic melanoma with new immunotherapy approaches beyond PD-1/CTLA-4 inhibitors	3
Educational needs of self-care in cachectic cancer patients and caregivers	3
Adjuvant and neoadjuvant approaches in pancreatic cancer	3
Real world data regarding the management of cancer-associated thrombosis	3
Highlighting recent treatment advances in metastatic prostate cancer: expanding the treatment arsenal	3
The path to personalized treatment in advanced and metastatic biliary tract cancers: a review of new targeted therapies and immunotherapy	3
Immune checkpoint inhibitors in driver mutation-positive nonsmall cell lung cancer: is there a role?	3
Ovarian preservation in gynecologic oncology: current indications and techniques	3
Pathology and new insights in central nervous system lymphomas	3
Novel next-generation sequencing-based methodologies to characterize the mutational consequences of (prenatal) chemotherapy exposure in noncancerous tissue	3
Maintenance therapies in acute myeloid leukemia: the renaissance of an old therapeutic concept	3
What is the standard indication of adjuvant or neoadjuvant chemotherapy in localized soft-tissue sarcoma?	3
A meta-analysis of the efficacy and toxicity of tyrosine kinase inhibitors in treating patients with different types of thyroid cancer: how to choose drugs appropriately?	3
Combining poly(ADP-ribose) polymerase inhibitors and immune checkpoint inhibitors in breast cancer: rationale and preliminary clinical results	3
Kirsten rat sarcoma inhibitors in clinical development against nonsmall cell lung cancer	3
Question prompt lists to improve communication between cancer patients and healthcare professionals	3
HTLV-1-related adult T-cell leukemia/lymphoma: insights in early detection and management	3
Nanoparticle therapy for head and neck cancers	3
Management of small bowel adenocarcinoma: making the most of the available evidence to inform routine practice	2
Treatment of anaplastic gliomas: evidences and controversies	2
HHV-8 associated lymphoma	2
Fasting-mimicking diet: a metabolic approach for the treatment of breast cancer	2
Physical approaches to treat glioblastoma	2
Selinexor therapy for multiple myeloma and non-Hodgkin lymphomas	2
The conquest of lung cancer in Central Europe	2
Recent advances in radiosensitivity determinants in melanoma	2
Treatment of small cell lung cancer: recent advances	2
High-risk, recurrent and oligometastatic prostate cancer: recent developments on the role of radiation	2
First and further-line multidisciplinary treatment of retroperitoneal sarcomas	2
Less is more in endometrial cancer (SLN, conservative treatment, radical hysterectomy, molecular classification)	2
Evolving systemic management of urothelial cancers	2
Rare driver alterations in nonsmall cell lung cancer: novel targeted drugs	2
Targeting molecular subtypes in solid cancers: successes and failures	2
The role and underlying mechanisms of tumour-derived exosomes in lung cancer metastasis	2
Update on bi-specific monoclonal antibodies for blood cancers	2
Active surveillance in favorable intermediate risk prostate cancer: outstanding questions and controversies	2
Surgical treatment for clinical early-stage expansile and infiltrative mucinous ovarian cancer: can staging surgeries safely be omitted?	2
Single agent vs combination immunotherapy in advanced melanoma: a review of the evidence	2
Local treatment in patients with hereditary breast cancer: decision-making process in low-, moderate-, high-penetrance pathogenic germline mutation carriers	2
Immunotherapies in non-metastatic gastrointestinal cancers	2
Pathologic diagnosis of lung cancer – recent developments	2
Deciphering diffuse glioma immune microenvironment as a key to improving immunotherapy results	2
Editorial: The challenge of treating and investigating rare gynaecologic cancers	2
Management of residual disease after chemotherapy in germ cell tumors	2
Interventions for children of parents with cancer: an overview	2
Liquid biopsy in head neck cancer: ready for clinical routine diagnostics?	2
Advances in management of nonendometrioid endometrial carcinoma, with an emphasis on the sentinel lymph node technique	2
Mind the target: circulating tumour DNA in gastrointestinal malignancies	2
New boundaries for fertility sparing management in endometrial cancer	2
Current treatment options for nodular lymphocyte-predominant Hodgkin lymphoma	2
Clinician's guide to targeted estrogen receptor degradation using PROTAC in patients with estrogen receptor-positive metastatic breast cancer	2
Emerging treatments in advanced urothelial cancer	2
Mind the target: human epidermal growth factor receptor 2 in colorectal cancer	2
Pediatric brain tumors as a developmental disease	2
Unveiling the enigma of the blood–brain barrier in glioblastoma: current advances from preclinical and clinical studies	2